Why A Structured System Matters 
How The System Helps You Succeed 
How Implementation Works 
What’s Included in the System 
Real Practice Outcomes 
Scaling a Profitable Practice 
Patient Demand 
Patient Education 
Staff Education 
Marketing 
Regenerative Medicine Platform
Franchise & PE Support 
Wharton’s Jelly
Exosomes
Anti-Aging
Aesthetic Treatments
Neurological
Autoimmune
Wound Care
Orthopedic Conditions
Clinical Trials
Articles
Research Institutes
AOD-9604 (Anti-Obesity Drug-9604) is a synthetic peptide fragment of human growth hormone (HGH), consisting of amino acids 176–191. Unlike full HGH, AOD-9604 does not stimulate IGF-1 production or general growth pathways. Instead, it has been studied primarily for its potential role in regulating fat metabolism. It remains experimental and is not FDA-approved as a therapy.
How It Is Used in Research Settings
- Explored for stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage) in adipose tissue models.
- Studied in obesity and metabolic syndrome research for weight management support.
- Examined in animal studies for potential effects on cartilage repair and joint health.
- Investigated as a safer alternative to HGH without impacting blood sugar or IGF-1 pathways.
Proposed Uses (Research Areas)
- Obesity and fat metabolism studies.
- Metabolic syndrome and insulin resistance models.
- Joint repair and cartilage protection (preclinical data).
- Aging and weight management research.
How It Is Dosed in Research Settings
- Injectable: Typically studied at 300 mcg to 600 mcg subcutaneously once daily.
- Oral formulations: Investigated in capsule form, though bioavailability and efficacy are less well established.
- Cycle length: Common research protocols range from 12–24 weeks for weight and metabolic outcomes.
- Handling: Supplied as a lyophilized powder; reconstituted with bacteriostatic water and stored refrigerated.
Important Considerations
- Regulatory status: AOD-9604 is not FDA-approved; all applications remain experimental.
- Evidence base: Most data comes from preclinical studies and small clinical trials; larger studies are needed.
- Safety: Reported as well tolerated in short studies, with low risk of hypoglycemia compared to HGH. Long-term safety is unknown.
Disclaimer
This material is provided for educational purposes only and summarizes published research on AOD-9604. It is not medical advice. AOD-9604 is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.
This peptide is for research use only.